News & Events about Travere Therapeutics Inc.
Travere Therapeutics (NASDAQ:TVTX Get Rating) had its price objective raised by Piper Sandler from $38.00 to $42.00 in a research report report published on Tuesday , The Fly reports. The firm currently has an overweight rating on the stock. Several other research analysts have also commented on the...
Company well-positioned for potential FDA Subpart H approval and commercial launch of sparsentan for IgA nephropathy (IgAN) in 1Q23, followed by potential EMA approval in second half of 2023 Preliminary net product sales of $201 million for the full year 2022 SANDIEGO, Jan. 09, 2023 (GLOBE ...
Stifel Nicolaus initiated coverage on shares of Travere Therapeutics (NASDAQ:TVTX Get Rating) in a report released on Tuesday , The Fly reports. The firm issued a hold rating and a $22.00 target price on the stock. A number of other brokerages have also commented on TVTX. Piper Sandler ...
Travere Therapeutics (NASDAQ:TVTX Get Rating) had its target price cut by SVB Leerink from $45.00 to $38.00 in a research note published on Thursday, MarketBeat Ratings reports. They currently have an outperform rating on the stock. Other analysts also recently issued research reports about the ...
Travere Therapeutics, Inc. (NASDAQ:TVTX Get Rating) insider Peter Heerma sold 3,042 shares of the stock in a transaction that occurred on Tuesday, October 4th. The stock was sold at an average price of $25.68, for a total value of $78,118.56. Following the completion of the transaction, the insider ...